• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 3
  3. Author

Online ISSN: 2515-8260

Volume9, Issue3

Evaluating Role of Topical Azithromycin in Meibomian Gland Dysfunction – An Interventional Study

    Yusuf Rizvi, Dushyant Upadhyay, Shivani Sharma

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 2734-2745

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background:Meibomian gland dysfunction (MGD) is a common ocular disorder, often underdiagnosed, and is a major contributory factor causing dry eye disease and ocular discomfort due to compromised quality of tears. A variety of physical measures, lubricants and antibiotics have been tried to alleviate the condition. Topical Azithromycin has been observed to provide relief in MGD. Interest has been generated in this drug due to its anti- inflammatory properties in addition to its antibiotic effect.
Materials and Methods: The present study was undertaken to study the clinical efficacy of topical Azithromycin in MGD. 70 patients randomly detected with MGD were given Azithromycin 1% topically. In half of the patients; n═35, (Group A), the mode of administration was aqueous as 1% eye drops, twice a day for 30 days while in remaining half (Group B), it was delivered as an ointment, applied daily at night for same duration. This was combined with physical measures of lid massage and lid hygiene. Primary outcome measures of evaluation were Fluorescein tear breakup time, (FTBUT)’, Tear quantification (Schirmer’s test), Corneal staining score, Meibomian gland score and a subjective clinical score. Measurements were recorded prior to drug usage and at subsequent follow up visits at Day 30, 60 & 90. Statistical analysis: Considering the small sample size, the outcome measures for the two groups were statistically analysed employing the Fischer’s exact test and the Mann Whitney test. P values (two sided) less than 0.05 were considered statistically significant.
Results: Azithromycin in aqueous form, showed significantly higher clinical efficacy at day 30, whereas noted efficacy of ointment was higher at day 60 and 90. The symptom score showed significant improvement among both the groups receiving azithromycin. The effect was however less significant for users of eye drops at day 90, compared to ointment. Values of Schirmer’s test echoed similar results.
Conclusion: Azithromycin 1% ophthalmic solution is effective in reducing the signs and symptoms associated with meibomian gland dysfunction in both, drop and ointment form. These effects persist in ocular tissues beyond the last application. However, long term effect of azithromycin seems better when used in the ointment form.
Keywords:
    Meibomian gland dysfunction azithromycin
  • PDF (484 K)
  • XML
(2022). Evaluating Role of Topical Azithromycin in Meibomian Gland Dysfunction – An Interventional Study. European Journal of Molecular & Clinical Medicine, 9(3), 2734-2745.
Yusuf Rizvi, Dushyant Upadhyay, Shivani Sharma. "Evaluating Role of Topical Azithromycin in Meibomian Gland Dysfunction – An Interventional Study". European Journal of Molecular & Clinical Medicine, 9, 3, 2022, 2734-2745.
(2022). 'Evaluating Role of Topical Azithromycin in Meibomian Gland Dysfunction – An Interventional Study', European Journal of Molecular & Clinical Medicine, 9(3), pp. 2734-2745.
Evaluating Role of Topical Azithromycin in Meibomian Gland Dysfunction – An Interventional Study. European Journal of Molecular & Clinical Medicine, 2022; 9(3): 2734-2745.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 96
  • PDF Download: 119
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus